Porter, M. P., Kerrigan, M. C., Donato, B. M. K. & Ramsey, S. D. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol. Oncol. 29, 252–258 (2011).

Article  PubMed  Google Scholar 

Yin, M. et al. Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis. Oncologist 21, 708–715 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Powles, T. et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N. Engl. J. Med. 391, 1773–1786 (2024).

Article  CAS  PubMed  Google Scholar 

Galsky, M. D. et al. Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer. Cell Rep. Med. 5, 101393 (2024).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sritharan, S. & Sivalingam, N. A comprehensive review on time-tested anticancer drug doxorubicin. Life Sci. 278, 119527 (2021).

Article  CAS  PubMed  Google Scholar 

Bajorin, D. F. et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N. Engl. J. Med. 384, 2102–2114 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Larkins, E. A phase III study of neoadjuvant/adjuvant durvalumab for the treatment of patients with resectable stage II/III non-small cell lung cancer (AEGEAN): contribution of treatment phase in perioperative trials (FDA, 2024).

Sammarco, E. et al. Immune checkpoint inhibitor rechallenge in renal cell carcinoma: current evidence and future directions. Cancers 15, 3172 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar